findmyKOL

Patrick Stiff, MD

Enriched profile

Director, Cardinal Bernardin Cancer Center; Director, Division of Hematology/Oncology; Coleman Professor of Oncology, Stritch School of Medicine · Loyola University Medical Center

ORCIDNPI
Region🇺🇸 Maywood, IL · Midwest · United StatesSpecialtyHematology / OncologyFocusLeukemia (AML/ALL/CML/CLL)+4
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2026Online presenceverified 2026Payments2021–2025NIH funding2002–2013

Patrick Stiff is Director, Cardinal Bernardin Cancer Center; Director, Division of Hematology/Oncology; Coleman Professor of Oncology, Stritch School of Medicine at Loyola University Medical Center. OpenAlex indexes 454 publications with 26,668 citations (h-index 64); ClinicalTrials.gov lists 15 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Hematology / Oncology profiles in the findmyKOL directory.

Data verified 14 Aug 2026

Overview

Updated 27 Aug 2026

Patrick J. Stiff, MD, is Director, Cardinal Bernardin Cancer Center at Loyola University Medical Center / Loyola Medicine (Trinity Health); Loyola University Chicago Stritch School of Medicine. The public record shows 454 publications with 26,668 citations (h-index 64), centered on Leukemia (AML/ALL/CML/CLL), MDS / MPN, Multiple Myeloma. It also documents an investigator role on 15 registered clinical trials, industry payments reported by 6 companies, 2 NIH-funded awards (2002–2013).

  • Most recent indexed publication: 2026 · Research square
  • Top research focus: Leukemia (AML/ALL/CML/CLL)
  • 15 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 6 companies

Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Lymphoma6 trialsOvarian / Gynecologic Cancer4 trialsLeukemia (AML/ALL/CML/CLL)4 trialsMDS / MPN4 trialsLeukemia, Myeloid, Acute4 trialsHodgkin Disease3 trialsHematologic Neoplasms2 trialsLeukemia, Lymphoid2 trialsVomiting1 trialNausea1 trialPrecursor Cell Lymphoblastic Leukemia-Lymphoma1 trialRecurrence1 trialLymphoma, Non-Hodgkin1 trialMultiple Myeloma1 trial

Research focus

OpenAlex concept fingerprint
Leukemia (AML/ALL/CML/CLL)MDS / MPNMultiple MyelomaLymphomaOvarian / Gynecologic Cancer

Drugs & molecules

across trials, industry payments and publications
OMISIRGEClinical trialsIndustry payments3PublicationsBesponsageneric · Inotuzumab ozogamicinClinical trialsIndustry payments2PublicationsBosulifgeneric · BosutinibClinical trialsIndustry payments1Publications

Works with

trial sponsors and companies reporting payments
Loyola UniversityClinical trials8Industry paymentsGamida Cell Inc.Clinical trialsIndustry payments3SWOG Cancer Research NetworkClinical trials3Industry payments

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
454publications

Distinct works indexed by OpenAlex, matched via ORCID; 11 in PubMed.

26,668citations

Total citations across indexed works.

64h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
15clinical trials

Investigator role on registered studies.

View trials
6companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments
2NIH grants · 2002–2013

Federally funded research awards.

View funding

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 27 Aug 2026

Listed as an investigator on 15 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 27 Aug 2026

6 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    100%
    Kinase inhibitor100%
    Calquence100%
    Part D<11 patients
Where care is delivered (Part B)100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 27 Aug 2026

2 NIH research awards on record, funded 20022013 per NIH RePORTER. The latest:

11 more award records behind the reveal.Reveal →

Publications

Updated 27 Aug 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Online presence

Updated 27 Aug 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/patrick-stiff-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com
  • ResearchGate

    researchgate.net/profile/Patrick-Stiff

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net
  • LinkedIn

    linkedin.com/in/patrick-stiff-060854b

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com

Mentions by others

where others cite or feature them
  • Facebook

    facebook.com/LeukemiaResearch/posts/dr-patrick-stiff-from-loyola-medicine-is-one-of-the-presenters-at-our-treatment-/10155962254836957

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →facebook.com
  • Facebook

    facebook.com/LoyolaHealth/posts/noted-loyola-oncologist-and-cancer-researcher-patrick-stiff-md-will-share-the-la/10156261345600559

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →facebook.com
  • Facebook

    facebook.com/loyolahealth/videos/patrick-j-stiff-md-awarded-stritch-medal/10154832302635559

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →facebook.com
1 more mention behind the reveal.Reveal →

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 27 Aug 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • Board Certification

    Hematology, American Board of Internal Medicine Subspecialty

    1982
    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →loyolamedicine.org
  • Fellowship

    Hematology and Medical Oncology, Memorial Sloan Kettering Cancer Center

    1981
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →loyolamedicine.org
  • Board Certification

    Medical Oncology, American Board of Internal Medicine Subspecialty

    1981
    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →loyolamedicine.org
  • Residency

    Internal Medicine, Cleveland Clinic Foundation

    1978
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →loyolamedicine.org
  • Board Certification

    Internal Medicine, American Board of Internal Medicine

    1978
    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →loyolamedicine.org
  • MD

    Loyola University Chicago Stritch School of Medicine

    1975
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →loyolamedicine.org
  • B.S. in Chemistry

    University of Toledo

    1972
    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →en.wikipedia.org

Editorial & leadership roles

journal and society appointments
  • Director

    Cardinal Bernardin Cancer Center, Loyola University Medical Center

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →loyolamedicine.org
  • Director

    Division of Hematology/Oncology, Stritch School of Medicine

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →eurekalert.org
  • Coleman Professor of Oncology

    Stritch School of Medicine

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →eurekalert.org
1 more role behind the reveal.Reveal →

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.